MSP-1014 has demonstrated greater efficacy at activating the 5-HT2A receptor and is showing signs of potential safety improvements
Mindset has selected End of Life Angst and Treatment-Resistant Depression as initial target indications for MSP-1014 and is currently undertaking IND enabling studies with MSP-1014, with a goal of entering Phase 1 clinical trials in 2022. The drug is a new chemical entity that is psilocybin-like in effect but has the potential to be a safer, more effective alternative. MSP-1014 has demonstrated superior safety and efficacy in head-to-head comparisons with psilocybin. Simpler and more cost-effective manufacturing will help to reduce the cost of the drug and Mindset believes that MSP-1014 represents an ideal drug to follow psilocybin in the clinic.